Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Ronald Richard sold 21,984 shares of the company's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the sale, the director owned 98,417 shares in the company, valued at $1,178,051.49. This trade represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Emergent Biosolutions Stock Performance
Emergent Biosolutions stock opened at $11.63 on Wednesday. The firm has a market capitalization of $610.55 million, a P/E ratio of 8.94 and a beta of 2.32. The stock has a fifty day moving average price of $10.27 and a two-hundred day moving average price of $8.41. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.41. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. The firm had revenue of $222.50 million during the quarter. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%. As a group, analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have weighed in on EBS shares. Wall Street Zen raised shares of Emergent Biosolutions from a "buy" rating to a "strong-buy" rating in a research note on Sunday, November 30th. Weiss Ratings reissued a "hold (c-)" rating on shares of Emergent Biosolutions in a report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Finally, Zacks Research upgraded Emergent Biosolutions to a "hold" rating in a research report on Friday, October 24th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $15.00.
Check Out Our Latest Analysis on EBS
Institutional Trading of Emergent Biosolutions
Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at approximately $31,000. Ameritas Investment Partners Inc. bought a new position in Emergent Biosolutions in the 2nd quarter valued at $35,000. Raymond James Financial Inc. bought a new position in Emergent Biosolutions in the 2nd quarter valued at $53,000. Janney Montgomery Scott LLC acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at $68,000. Finally, ProShare Advisors LLC bought a new stake in shares of Emergent Biosolutions during the second quarter worth $71,000. 78.40% of the stock is owned by institutional investors.
Emergent Biosolutions Company Profile
(
Get Free Report)
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
